Global Infantile Hemangioma Market, By Treatment Type (Medication, Surgery, Laser Treatment), Drug Type (Beta-Blocker and Steroids), Route of Administration (Oral, Injectables and Others), Diagnosis (X-Ray, Computerized Tomography (CT) Scans, Biopsy, Angiogram and Others), End User (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy, Others), Country (U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E., Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa) Industry Trends and Forecast to 2028
Market Analysis and Insights: Global Infantile Hemangioma Market
The infantile hemangioma market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses the market is growing at a CAGR of 3.2% in the above-mentioned research forecast period. Increase in research and development related to the treatment of infantile hemangioma can drive the infantile hemangioma market growth.
Infantile hemangioma (IH) is the most common type of vascular tumors. It mainly occurs in 5% of infants making them the most common benign tumour. In this, the blood vessels get scrambled or form a cluster in or under the skin of baby. It occurs when there is a proliferation of both vascular and endothelial cells that is distributed on face, head and neck. It becomes visible in first few days to weeks after the birth of the baby. There are two different types of IH that is superficial hemangiomas that grows on the surface of the skin and the other one is deep hemangiomas that grow under the skin. Sometimes, the hemangioma grows inside the organs such as kidney, liver or brain that cannot be seen at the early stage of the birth. In most of the cases, IH is harmless and disappears at the age of 5 months or 1 year. But in some patient population, the IH leaves the permanent scar, disfigurement and causes pain, bleeding, ulceration which needs a personal attention and treatment.
The incidence of the infantile hemangioma is 4-5% and rise in prevalence of hemangioma mainly in non-hispanic white female babies may drive the infantile hemangioma market growth. Different therapeutic regimens such as oral, injectables and topical medications in combination with the treatments such as laser, surgical and observational treatment drives the infantile hemangioma market. Moreover, the discovery of new treatments as well as new drugs for the treatment of IH may increase the market growth for the infantile hemangioma. In addition, increase in awareness programs about the infantile hemangioma increases the infantile hemangioma market growth. For instance, American Academy of Pediatrics has organized an awareness programs through webinar. But the side-effects related to treatment, poor efficacy rate and high cost of therapies may hamper the growth of infantile hemangioma market. One of the challenges for the infantile hemangioma market is stringent approval policies for new therapies. Similarly, the management of IH differ from patient to patient and adequate knowledge about the treatment mode is a challenging task for the physicians.
The estimated cost of the IH treatment for the outpatient was USD 138 with additional charges of USD 828 for echocardiogram. Similarly, for inpatient, the cost was USD 2,603 with additional charges of USD 2,843 for echocardiogram. Therefore, the better choice for the treatment of outpatients is propranolol (2 to 3 mg/kg per day) which is considered as a cost-effective treatment and can increase the infantile hemangioma market growth of propranolol drug. For instance, in March 2014, Pierre Fabre Group has received FDA approval for the marketing of hemangeol oral solution of propranolol hydrochloride which is the first and only approved treatment for infantile hemangioma. It was specially formulated for the children dealing with the hemangioma and was available on June 2014 in market.
This infantile hemangioma market provides details of market share, new developments and product pipeline analysis, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions and technological innovations in the market. To understand the analysis and the infantile hemangioma market scenario contact Data Bridge Market Research for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.
Infantile Hemangioma Market Scope and Market Size
The infantile hemangioma market is segmented on the basis of treatment type, drug type, route of administration, diagnosis, end-user and distribution channel. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
- On the basis of treatment type, the infantile hemangioma market is segmented into medication, surgery and laser treatment
- On the basis of drug type, the infantile hemangioma market is segmented into beta-blockers and steroids. Beta-blockers are further segmented to propranolol, timolol, atenolol, nadolol whereas steroids are sub-segmented to methylprednisolone, prednisolone and triamcinolone.
- On the basis of route of administration, the infantile hemangioma market is segmented into oral, injectables and others.
- On the basis of diagnosis, the infantile hemangioma market is segmented into X-ray, computerized tomography (CT) scans, biopsy, angiogram and others.
- On the basis of end-user, the infantile hemangioma market is segmented into hospitals, homecare, specialty clinics and others
- On the basis of distribution channel, the infantile hemangioma market has also been segmented into hospital pharmacy, online pharmacy, retail pharmacy and others.
Global Infantile Hemangioma Market Country Level Analysis
Global infantile hemangioma market is analysed and market size information is provided by country, treatment type, drug type, route of administration, diagnosis, end-user and distribution channel as referenced above.
The countries covered in the infantile hemangioma market report are the U.S., Canada, Mexico in North America, Brazil, Argentina, Peru, Rest of South America, as part of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa, as a part of Middle East and Africa.
On geographical estimation, North America accounts the largest market share due to rise in healthcare expenditure and due to availability of advanced treatments and products. The infantile hemangioma market players are mainly from the region which makes the largest market share. Europe accounts the second largest market share due to increased cases of infantile hemangioma and high government support for research and development of novel drugs.
The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Patient Epidemiology Analysis
The infantile hemangioma market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to infantile hemangioma market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the infantile hemangioma market in the growth period.
Competitive Landscape and Infantile Hemangioma Market Share Analysis
The infantile hemangioma market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, clinical trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to infantile hemangioma market.
The major players covered in the infantile hemangioma market report are Pierre Fabre Group, BIOLASE, Inc., Bausch Health, Cutera, Teva Pharmaceutical Industries Ltd., IRIDEX Corporation, Alma Lasers Ltd, LINLINE Medical Systems Ltd., Merck & Co., Inc., AbbVie Inc., ALLERGAN, Akorn, Pfizer Inc., AstraZeneca among other domestic and global players. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.
SKU-